{"id":"https://openalex.org/W2765178666","doi":"https://doi.org/10.1007/s00280-017-3469-4","title":"A drug\u2013drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors","display_name":"A drug\u2013drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors","publication_year":2017,"publication_date":"2017-11-03","ids":{"openalex":"https://openalex.org/W2765178666","doi":"https://doi.org/10.1007/s00280-017-3469-4","mag":"2765178666","pmid":"https://pubmed.ncbi.nlm.nih.gov/29101463"},"language":"en","primary_location":{"id":"doi:10.1007/s00280-017-3469-4","doi":"https://doi.org/10.1007/s00280-017-3469-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-017-3469-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-017-3469-4.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://link.springer.com/content/pdf/10.1007/s00280-017-3469-4.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006165743","display_name":"Vincent A. de Weger","orcid":"https://orcid.org/0000-0002-1658-9222","observed_orcids":["https://orcid.org/0000-0002-1658-9222"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Vincent A. de Weger","raw_affiliation_strings":["Division of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands"],"raw_orcid":"https://orcid.org/0000-0002-1658-9222","affiliations":[{"raw_affiliation_string":"Division of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029455802","display_name":"Sanjay Goel","orcid":"https://orcid.org/0000-0002-2798-7568","observed_orcids":["https://orcid.org/0000-0002-2798-7568"]},"institutions":[{"id":"https://openalex.org/I129975664","display_name":"Albert Einstein College of Medicine","ror":"https://ror.org/05cf8a891","country_code":"US","type":"education","lineage":["https://openalex.org/I129975664","https://openalex.org/I4210112371"]},{"id":"https://openalex.org/I1335289525","display_name":"Montefiore Medical Center","ror":"https://ror.org/044ntvm43","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1335289525","https://openalex.org/I19772626"]},{"id":"https://openalex.org/I4390039242","display_name":"Montefiore Einstein Comprehensive Cancer Center","ror":"https://ror.org/00cea8r21","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I129975664","https://openalex.org/I4210112371","https://openalex.org/I4390039242"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Goel","raw_affiliation_strings":["Albert Einstein Cancer Center, Montefiore Medical Center, 111 E 210th Street, Bronx, NY, 10567, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Albert Einstein Cancer Center, Montefiore Medical Center, 111 E 210th Street, Bronx, NY, 10567, USA","institution_ids":["https://openalex.org/I129975664","https://openalex.org/I1335289525","https://openalex.org/I4390039242"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025804381","display_name":"Roger von Moos","orcid":"https://orcid.org/0000-0003-2362-8514","observed_orcids":["https://orcid.org/0000-0003-2362-8514"]},"institutions":[{"id":"https://openalex.org/I4210148531","display_name":"Kantonsspital Graub\u00fcnden","ror":"https://ror.org/04wpn1218","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210148531"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Roger von Moos","raw_affiliation_strings":["Department of Internal Medicine, Kantonsspital Graub\u00fcnden, Loestrasse 170, 7000, Chur, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Kantonsspital Graub\u00fcnden, Loestrasse 170, 7000, Chur, Switzerland","institution_ids":["https://openalex.org/I4210148531"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000418012","display_name":"Jan H.M. Schellens","orcid":"https://orcid.org/0000-0001-6832-1976","observed_orcids":["https://orcid.org/0000-0001-6832-1976"]},"institutions":[{"id":"https://openalex.org/I193662353","display_name":"Utrecht University","ror":"https://ror.org/04pp8hn57","country_code":"NL","type":"education","lineage":["https://openalex.org/I193662353"]},{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":true,"raw_author_name":"Jan H. M. Schellens","raw_affiliation_strings":["Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584CG, Utrecht, The Netherlands. J.Schellens@nki.nl","Division of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. J.Schellens@nki.nl","Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584CG, Utrecht, The Netherlands"],"raw_orcid":"https://orcid.org/0000-0001-6832-1976","affiliations":[{"raw_affiliation_string":"Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584CG, Utrecht, The Netherlands. J.Schellens@nki.nl","institution_ids":["https://openalex.org/I193662353"]},{"raw_affiliation_string":"Division of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. J.Schellens@nki.nl","institution_ids":["https://openalex.org/I2898336195"]},{"raw_affiliation_string":"Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584CG, Utrecht, The Netherlands","institution_ids":["https://openalex.org/I193662353"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049247978","display_name":"Nicholas Mach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106256","display_name":"University Hospital of Geneva","ror":"https://ror.org/01m1pv723","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210106256"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nicholas Mach","raw_affiliation_strings":["Division of Oncology, University Hospital of Gen\u00e8ve, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology, University Hospital of Gen\u00e8ve, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland","institution_ids":["https://openalex.org/I4210106256"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101882884","display_name":"Jin Quan Eugene Tan","orcid":"https://orcid.org/0009-0001-1742-2387","observed_orcids":["https://orcid.org/0009-0001-1742-2387"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eugene Tan","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023484384","display_name":"Suraj P. Anand","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suraj Anand","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077479346","display_name":"Jeffrey W. Scott","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey W. Scott","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ, 07936, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077199450","display_name":"Ulrik Lassen","orcid":"https://orcid.org/0000-0002-3865-4574","observed_orcids":["https://orcid.org/0000-0002-3865-4574"]},"institutions":[{"id":"https://openalex.org/I2802709434","display_name":"Rigshospitalet","ror":"https://ror.org/03mchdq19","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2802567020","https://openalex.org/I2802709434","https://openalex.org/I4210145385"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Ulrik Lassen","raw_affiliation_strings":["Department of Oncology, Rigshospitalet, Blegsdamsvej 9, 2100, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Rigshospitalet, Blegsdamsvej 9, 2100, Copenhagen, Denmark","institution_ids":["https://openalex.org/I2802709434"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5000418012"],"corresponding_institution_ids":["https://openalex.org/I193662353","https://openalex.org/I2898336195"],"apc_list":{"value":4390,"currency":"USD","value_usd":4390},"apc_paid":null,"fwci":0.2907,"has_fulltext":true,"cited_by_count":4,"citation_normalized_percentile":{"value":0.6250447,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"81","issue":"1","first_page":"73","last_page":"80"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dovitinib","display_name":"dovitinib","score":0.984000027179718},{"id":"https://openalex.org/keywords/fluvoxamine","display_name":"fluvoxamine","score":0.9850000143051147},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cyp1a2-inhibition","display_name":"CYP1A2 inhibition","score":0.9599999785423279},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8920000195503235},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9010000228881836},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8650000095367432},{"id":"https://openalex.org/keywords/vegfr-inhibition","display_name":"VEGFR inhibition","score":0.6949999928474426},{"id":"https://openalex.org/keywords/fgfr-inhibition","display_name":"FGFR inhibition","score":0.7039999961853027},{"id":"https://openalex.org/keywords/pdgfr-inhibition","display_name":"PDGFR inhibition","score":0.968999981880188},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.6290000081062317}],"concepts":[{"id":"https://openalex.org/C2779910183","wikidata":"https://www.wikidata.org/wiki/Q409236","display_name":"Fluvoxamine","level":5,"score":0.9053695201873779},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8795943260192871},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7549867630004883},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.7228001356124878},{"id":"https://openalex.org/C86745063","wikidata":"https://www.wikidata.org/wiki/Q3737406","display_name":"CYP1A2","level":4,"score":0.5922300219535828},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.5595281720161438},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43475541472435},{"id":"https://openalex.org/C2910466267","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug-drug interaction","level":3,"score":0.4216257929801941},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36989039182662964},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19691592454910278},{"id":"https://openalex.org/C526171541","wikidata":"https://www.wikidata.org/wiki/Q407693","display_name":"Cytochrome P450","level":3,"score":0.1788630187511444},{"id":"https://openalex.org/C62231903","wikidata":"https://www.wikidata.org/wiki/Q1057","display_name":"Metabolism","level":2,"score":0.10383939743041992},{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.08778619766235352},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001562","descriptor_name":"Benzimidazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016666","descriptor_name":"Fluvoxamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065609","descriptor_name":"Cytochrome P-450 CYP1A2 Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D065609","descriptor_name":"Cytochrome P-450 CYP1A2 Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D065609","descriptor_name":"Cytochrome P-450 CYP1A2 Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D065609","descriptor_name":"Cytochrome P-450 CYP1A2 Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1007/s00280-017-3469-4","doi":"https://doi.org/10.1007/s00280-017-3469-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-017-3469-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-017-3469-4.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},{"id":"pmid:29101463","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29101463","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer chemotherapy and pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:dspace.library.uu.nl:1874/362848","doi":null,"is_oa":true,"landing_page_url":"https://dspace.library.uu.nl/handle/1874/362848","pdf_url":null,"source":{"id":"https://openalex.org/S4306401649","display_name":"Utrecht University Repository (Utrecht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I193662353","host_organization_name":"Utrecht University","host_organization_lineage":["https://openalex.org/I193662353"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/e8b051a0-e2ad-4c90-8b12-b25ef3fe2303","doi":null,"is_oa":false,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/e8b051a0-e2ad-4c90-8b12-b25ef3fe2303","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"de Weger, V A, Goel, S, von Moos, R, Schellens, J H M, Mach, N, Tan, E, Anand, S, Scott, J W & Lassen, U 2018, 'A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors', Cancer Chemotherapy and Pharmacology, vol. 81, no. 1, pp. 73-80. https://doi.org/10.1007/s00280-017-3469-4","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:unige.ch:aou:unige:175787","doi":null,"is_oa":true,"landing_page_url":"https://archive-ouverte.unige.ch/unige:175787","pdf_url":null,"source":{"id":"https://openalex.org/S4306402259","display_name":"Archive ouverte UNIGE (University of Geneva)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114457229","host_organization_name":"University of Geneva","host_organization_lineage":["https://openalex.org/I114457229"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ISSN: 0344-5704","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:uu:oai:dspace.library.uu.nl:1874/362848","doi":null,"is_oa":false,"landing_page_url":"https://dspace.library.uu.nl/handle/1874/362848","pdf_url":null,"source":{"id":"https://openalex.org/S4306401649","display_name":"Utrecht University Repository (Utrecht University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I193662353","host_organization_name":"Utrecht University","host_organization_lineage":["https://openalex.org/I193662353"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Cancer Chemotherapy and Pharmacology, 81(1), 73. Springer Verlag","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1007/s00280-017-3469-4","doi":"https://doi.org/10.1007/s00280-017-3469-4","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00280-017-3469-4","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00280-017-3469-4.pdf","source":{"id":"https://openalex.org/S117498271","display_name":"Cancer Chemotherapy and Pharmacology","issn_l":"0344-5704","issn":["0344-5704","1432-0843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Chemotherapy and Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320310388","display_name":"Novartis Pharmaceuticals Corporation","ror":"https://ror.org/028fhxy95"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2765178666.pdf","grobid_xml":"https://content.openalex.org/works/W2765178666.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W1630482321","https://openalex.org/W1838206777","https://openalex.org/W1893424794","https://openalex.org/W1971340381","https://openalex.org/W1971800064","https://openalex.org/W2003197532","https://openalex.org/W2007983159","https://openalex.org/W2009309230","https://openalex.org/W2013587785","https://openalex.org/W2023580320","https://openalex.org/W2025533780","https://openalex.org/W2025930315","https://openalex.org/W2045654730","https://openalex.org/W2050328756","https://openalex.org/W2058206040","https://openalex.org/W2068633458","https://openalex.org/W2072972015","https://openalex.org/W2118101333","https://openalex.org/W2127385754","https://openalex.org/W2128288739","https://openalex.org/W2130440144","https://openalex.org/W2140656090","https://openalex.org/W2146807741","https://openalex.org/W2157227177","https://openalex.org/W2171961428","https://openalex.org/W2341791135"],"related_works":["https://openalex.org/W2603218970","https://openalex.org/W7214108927","https://openalex.org/W1983883911","https://openalex.org/W2965599789","https://openalex.org/W2752435257","https://openalex.org/W4205185242","https://openalex.org/W1905382513","https://openalex.org/W2314641883","https://openalex.org/W2047993460","https://openalex.org/W2966572071"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-11-10T00:00:00"}